Patents Examined by Marianne P. Allen
-
Patent number: 12129308Abstract: The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.Type: GrantFiled: June 4, 2018Date of Patent: October 29, 2024Assignees: MERCK PATENT GMBH, ABLYNX NVInventors: Francis Descamps, Gerald Beste, Guy Hermans, Hans Guehring, Lars Toleikis, Christoph Ladel
-
Patent number: 12122821Abstract: The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.Type: GrantFiled: July 12, 2019Date of Patent: October 22, 2024Assignee: H. LUNDBECK A/SInventors: Brian Baker, Jeffrey T.L. Smith, John Latham
-
Patent number: 12116405Abstract: Administration of a monoclonal Ab (mAb) that specifically targets IL-1? is useful to treating articular and extra-articular symptoms of arthritis.Type: GrantFiled: June 21, 2022Date of Patent: October 15, 2024Assignee: XBIOTECH INC.Inventor: John Simard
-
Patent number: 12110332Abstract: A bifunctional fusion protein targeting CD47 and PD-L1, which belongs to the field of biomedicine and solves the problems that anti-PD-1/PD-L1 treatment has poor effect on low immunogenic tumors and anti-CD47 treatment has poor targeting properties. The fusion protein consists of a CD47-binding moiety and a PD-L1-binding moiety linked by means of a disulfide bond, can block both the binding of CD47 to SIRPa and the binding of PD-L1 to PD-1, not only activating macrophage phagocytosis of tumor cells and promoting antigen presentation in innate immunity, but also promoting tumor-specific T cell activation in acquired immunity, and has lower hematological toxicity. The fusion protein has better anti-tumor efficacy and hematological safety than anti-PD-L1 or anti-CD47 therapy alone, and animals from which a tumor has disappeared after the treatment of the fusion protein produce immunity against re-inoculation of the same tumor cell.Type: GrantFiled: November 20, 2017Date of Patent: October 8, 2024Assignee: Taizhou Mabtech Pharmaceutical Co., Ltd.Inventor: Yajun Guo
-
Patent number: 12071476Abstract: The present invention provides antagonizing antibodies that bind to IL-6, fusion proteins thereof with VEGF Trap, and conjugates of either thereof, and methods of using same. The anti-IL-6 antibodies can be used therapeutically alone or in combination with other therapeutics to diseases.Type: GrantFiled: March 1, 2019Date of Patent: August 27, 2024Assignee: KODIAK SCIENCES INC.Inventors: Rachel D. Jacobson, Fernando Corrêa, Hong Liang, Daniel Victor Perlroth
-
Patent number: 12064470Abstract: The present invention relates to the activation of FGF10 signaling pathway for use in the treatment of a heart disease.Type: GrantFiled: November 16, 2018Date of Patent: August 20, 2024Assignees: UNIVERSITE D'AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventor: Francesca Nadège Joëlle Rochais
-
Patent number: 12065487Abstract: The present disclosure relates to an antigen-binding molecule that specifically binds to nerve growth factor (NGF) and uses thereof.Type: GrantFiled: June 21, 2023Date of Patent: August 20, 2024Assignee: Scout Bio, Inc.Inventors: Samantha J. Busfield, Matthew J. Wilson
-
Patent number: 12060396Abstract: Disclosed herein are compositions and methods for inhibiting collagen production mediated by the Fused in Sarcoma (FUS) ribonucleoprotein. As disclosed herein, the C terminal domain of FUS contains an uncommon nuclear localization sequence (NLS) motif called PY-NLS that binds the nuclear import receptor transportin. Phosphorylation of FUS leads to its association with transportin and nuclear translocation with consequent increased in collagen production. Therefore, disclosed herein is an isolated peptide having a transportin-binding moiety, which inhibits FUS from binding transportin, linked to a membrane translocating motif. These compositions and methods can be used to inhibit FUS-mediated collagen production, and treat fibrotic disease involving FUS-mediated collagen accumulation in kidneys and other organs displaying fibrotic diseases.Type: GrantFiled: January 29, 2018Date of Patent: August 13, 2024Assignees: Vanderbilt University, The United States as Represented by the Department of Veterans AffairsInventors: Ambra A. Pozzi, Manuel Chiusa, Jack J. Hawiger, Jozef Zienkiewicz
-
Patent number: 12060416Abstract: The present invention belongs to the field of tumor immunotherapy, and relates to a humanized monoclonal antibody that binds to VEGF. The present invention discloses nucleic acid sequences (including heavy/light chain variable regions) encoding said antibodies, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The antibody disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2. Said antibodies also neutralize the proliferative effect of VEGF165 protein and multiple VEGF subtypes on HUVEC cells and can be used in clinical treatment of tumors, including but not limited to: colorectal cancer.Type: GrantFiled: January 19, 2022Date of Patent: August 13, 2024Assignee: SinoCellTech Ltd.Inventors: Liangzhi Xie, Chunyun Sun, Rui Wang, Xiao Zhang
-
Patent number: 12048728Abstract: The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble Fc?RIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.Type: GrantFiled: January 25, 2022Date of Patent: July 30, 2024Inventors: Peter Sondermann, Thomas Pohl
-
Patent number: 12043664Abstract: Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.Type: GrantFiled: September 21, 2020Date of Patent: July 23, 2024Assignee: EyePoint Pharmaceuticals, Inc.Inventors: Kevin Peters, Robert Shalwitz
-
Patent number: 12043667Abstract: Provided herein are VHH-containing polypeptides that bind CLEC12a. Uses of the VHH-containing polypeptides are also provided.Type: GrantFiled: May 1, 2020Date of Patent: July 23, 2024Assignee: Inhibrx Biosciences, Inc.Inventors: Lucas Rascon, Angelica Sanabria, John C. Timmer, Brendan P. Eckelman
-
Patent number: 12030941Abstract: The present invention provides novel anti-PD-1 antibodies that specifically bind to cell surface PD-1. Also provided are the nucleic acid molecules encoding the anti-PD-1 antibodies, expression vectors and host cells used for the expression of the anti-PD-1 antibodies. The invention further provides the methods for producing the anti-PD-1 antibodies and the use thereof.Type: GrantFiled: March 18, 2019Date of Patent: July 9, 2024Assignee: WUXI BIOLOGICS IRELAND LIMITEDInventors: Yunying Chen, Jing Li
-
Patent number: 12024562Abstract: The present invention refers to an antibody against Tie-2 or antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a manufacturing method of the antibody or antigen-binding fragment thereof, and a composition for preventing or treating angiogenic diseases, which comprises the antibody or antigen-binding fragment thereof.Type: GrantFiled: December 3, 2020Date of Patent: July 2, 2024Assignee: Institute for Basic ScienceInventors: Gou Young Koh, Jeomil Bae, Jaeryung Kim
-
Patent number: 12018081Abstract: A prodrug enzyme covalently photoconjugated to a live cell receptor survives endosomal proteolysis and retains its catalytic activity on the living cell membrane over multiple days. Antibody-directed enzyme prodrug therapy is a promising approach for selective treatment of solid tumors, but methods are needed to preserve enzyme activity on living cell membranes over multiple prodrug dosings. A fusion protein was designed with both an anti-epidermal growth factor receptor (EGFR) affibody and the prodrug enzyme cytosine deaminase, which can convert prodrug 5-fluorocytosine to the anticancer drug 5-fluorouracil. A benzophenone group was added at a site-specific mutation within the affibody portion, and the fusion protein was selectively and irreversibly photoconjugated to EGFR receptors expressed on membranes of live MDA-MB-468 breast cancer cells.Type: GrantFiled: August 28, 2020Date of Patent: June 25, 2024Assignee: The Regents of the University of Colorado, a body corporateInventors: Andrew P. Goodwin, Jennifer N. Cha, Shambojit Roy, Michael D. Brasino
-
Patent number: 12006352Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: GrantFiled: March 19, 2020Date of Patent: June 11, 2024Assignees: Ablynx N.V., SanofiInventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Patent number: 12006351Abstract: Provided are compositions and methods for inhibiting extracellular matrix metalloproteinase-2 (MMP-2) activity. Inhibition of extracellular MMP-2 activity can be useful for restricting extracellular matrix remodeling, tumor cell migration, cell invasion, and/or metastasis. The compositions comprise mutants of Tissue Inhibitor of Metalloproteinase-2 (TIMP-2), where the tyrosine at position 62, 90 and/or 165 has been substituted with a non-phosphorylatable amino acid or with a phosphomimetic of phosphorylated tyrosine, and/or anti-Src antibodies. The method comprises delivering to an extracellular region of a tissue, a composition comprising a TIMP-2 mutant and/or an anti-Src antibody.Type: GrantFiled: June 30, 2017Date of Patent: June 11, 2024Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Dimitra Bourboulia, Mehdi Mollapour, Gennady Bratslavsky
-
Patent number: 12006368Abstract: The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.Type: GrantFiled: December 19, 2018Date of Patent: June 11, 2024Assignee: Surrozen Operating, Inc.Inventors: Yang Li, Tom Zhiye Yuan, Aaron Ken Sato, Wen-Chen Yeh, Chenggang Lu, Parthasarathy Sampathkumar, Claudia Yvonne Janda
-
Patent number: 11999782Abstract: The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.Type: GrantFiled: August 24, 2020Date of Patent: June 4, 2024Assignees: Fundació Privada Institutció Catalana de Recerca I Estudis Avançats (ICREA), Fundació Privada Institut D'Investigatió Oncológica De Vall Hebron (VHIO), Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron (IR-HUVH)Inventors: Joan Seoane Suarez, Silvia Penuelas Prieto, José Baselga Torres
-
Patent number: 11999787Abstract: The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.Type: GrantFiled: March 22, 2021Date of Patent: June 4, 2024Assignee: Genentech, Inc.Inventors: Minhong Yan, Gu Zhang, Nicholas John Agard, Danielle Marie Dicara, Philip E. Hass, Julie Q. Hang, Erin L. Christensen, Robert Paul Morse, Sarah Sanowar, Vittal Shivva